Patents by Inventor Jacob Freeman Archer

Jacob Freeman Archer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS
    Publication number: 20220088177
    Abstract: The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.
    Type: Application
    Filed: September 3, 2021
    Publication date: March 24, 2022
    Applicant: Immune Design Corp.
    Inventors: Peter Lars Aksel Berglund, Jacob Freeman Archer, Tsai-yu Lin
  • RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS
    Publication number: 20220054627
    Abstract: The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 24, 2022
    Applicant: Immune Design Corp.
    Inventors: Peter Lars Aksel Berglund, Jacob Freeman Archer, Tsai-yu Lin
  • Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids
    Patent number: 11135283
    Abstract: The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 5, 2021
    Assignee: Immune Design Corp.
    Inventors: Peter Lars Aksel Berglund, Jacob Freeman Archer, Tsai-Yu Lin
  • A RETROVIRAL VECTOR FOR THE ADMINISTRATION AND EXPRESSION OF REPLICON RNA EXPRESSING HETEROLOGOUS NUCLEIC ACIDS
    Publication number: 20200254087
    Abstract: The present disclosure relates generally to gene delivery using a chimeric, retroviral-RNA replicon vector particle for increased expression of transgenes in a host cell. In particular, the chimeric vectors described herein can be used in any of a variety of settings including gene therapy and vaccine settings.
    Type: Application
    Filed: November 9, 2016
    Publication date: August 13, 2020
    Inventors: Peter Lars Aksel Berglund, Jacob Freeman Archer, Tsai-Yu Lin